Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease

NCT00327301 | Withdrawn

• 1 other identifier: 075-WUK-2006-001
• Study Type: observational
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier studies the investigators could demonstrate that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential mRNA expression and an increased fragmentation of the DNA. Such alterations point out a relationship between cellular stress and apoptotic events. Based on the results of mRNA-expression the investigators also expect alterations on the protein level. This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways. Thus, the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with samples from healthy controls. In addition, they will also be compared with samples from patients with Parkinson's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as positive controls in this study.

Conditions

Parkinson's Disease; Glaucoma

Keywords

POAG; Parkinson's disease; cellular proteome; human leucocytes; vasospasm; POAG patients; Patients with Parkinson's disease; Healthy subjects

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

glaucoma patients

You may qualify if:

• German native speakers
• Age between 18-85 years
• Primary open-angle glaucoma (POAG) with and without vasospasm

You may not qualify if:

• Any history of:
• Ocular or systemic diseases other than glaucoma or Parkinson's disease
• Drug or alcohol abuse
• Any condition potentially interfering with the visual field results. Visual fields will be obtained from the chart.
• Mental impairment interfering with the ability to cooperate and understand the purpose of this study; exception: those patients with Parkinson's disease. A prerequisite for including patients with Parkinson's disease in this study is the ability of these patients to cooperate and completely understand the purpose of this study.

Sponsors & Collaborators

• University Hospital, Basel, Switzerland: lead
• University of Bonn: collaborator

Biospecimen

Retention: NONE RETAINED

plasma

MeSH Terms

Conditions

Parkinson Disease; Glaucoma

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Ocular Hypertension; Eye Diseases

Study Officials

• Selim Orgül, MD

  University Hospital, Basel, Switzerland

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 17, 2006
• First Posted: May 18, 2006
• Study Start: October 1, 2006
• Primary Completion: May 1, 2008
• Last Updated: March 10, 2015

Record last verified: 2015-03